Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.

Slides:



Advertisements
Similar presentations
Investigator Responsibilities in Clinical Research
Advertisements

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Good Medical Practice Evidence to use for Appraisal Good Medical Practice 2006.
Tips to a Successful Monitoring Visit
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Good Clinical Research Practice Guidelines For Informed Consent Presented by Catherine May Acting Research Practice Development Officer The Office of Research.
The Consent Process: It’s More Than Just a Form A “10 Minute Training” Brought to you by Cyndi Long, MS, RD, CCRC CU Sports Medicine.
Good Clinical Practice in Research
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Post-trial Access to Treatment by Patients participating in Clinical Trials Presented by Dr T K S Letlape Chairman: South African Medical Association President-Elect:
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Good Clinical Practice GCP
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Introduction to Clinical Protocol
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Workshop on Health Examination Surveys (HES) Legal and ethical issues Susanna Conti, M. Kanieff, G. Rago Istituto Superiore di Sanità (ISS) (National Public.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Overview of the Clinical Trial & Protocol Jane Fendl March 31, 2010
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
May I have your permission please? The consent process: What, Where, When, Who and Why Valerie Smith OHRP IRB Program Manager
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
EXPERIMENTAL EPIDEMIOLOGY
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Investigational Devices and Humanitarian Use Devices June 2007.
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Supervisory Responsibilities of Clinical Investigators
Good Clinical Practice (GCP) and Monitoring Practices
Susan Sonne, PharmD, BCPP Chair, MUSC IRB II
Back to Basics – Approval Criteria
Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
CLINICAL PROTOCOL DEVELOPMENT
Enrolling in Clinical Trials
Administering Informed Consent Issues for Discussion
Within Trial Decisions: Unblinding and Termination
Good Clinical Practice
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Jeffrey M. Cohen, Ph.D. CIP President HRP Associates, Inc.
Bozeman Health Clinical Research
Critical Reading of Clinical Study Results
Ethical Principles of Research
راهنماي اختصاصي اخلاق در كارآزمايي هاي باليني
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Development Plans: Study Design and Dose Selection
Informed Consent in Clinical Trials
TRTO (Translational Research Trials Office)
Protocol Approval Criteria
Good clinical practice
Presentation transcript:

Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C

In this session Essential clinical trials documents and materials Essential clinical trials documents and materials Definition of the protocol Definition of the protocol How to write a clinical study protocol How to write a clinical study protocol Ethical Considerations: The declaration of Helsinki Ethical Considerations: The declaration of Helsinki Informed consent Informed consent Case record forms. Case record forms. Current Compliance Concerns (FDA) Current Compliance Concerns (FDA)

Basic Documents and materials of clinical trials Clinical Trial Protocol Clinical Trial Protocol Informed Consent form Informed Consent form Trial Case Record Forms (CRF) Trial Case Record Forms (CRF) Investigational Product Investigational Product Study Materials Study Materials

Definition Of the Protocol (according to ICH Good Clinical Practice Guideline) A document that describes the objective(s), design, methodology, statistical considerations, and organisation of the trial. A document that describes the objective(s), design, methodology, statistical considerations, and organisation of the trial. Usually, the protocol also gives the background and rational for the trial. Usually, the protocol also gives the background and rational for the trial.

How to write a protocol How detailed should a protocol be: How detailed should a protocol be: –This is a matter of judgement –Rule of thumb: Include the right amount of detail necessary for the reader of each section to be able to understand exactly what is required to conduct the study.

Start by mapping out a study schedule Visit 1 Baseline (day 0) Visit 2 Randomization(day10) Visit 3 (day 20) Follow-upVisit (after end of treatment) Informed Consent X Inclusion/ Exclusion X Medical History X Primary diagnosis X Clinical assessment XXXX RandomisationX Adverse Events XXX Assessment of relapse X

Objectives and end-points Get the primary objective right Get the primary objective right The primary objective will dictate the primary end-point. The primary objective will dictate the primary end-point. Primary end point measurement will be used to calculate sample size. Primary end point measurement will be used to calculate sample size.

Get the primary objective right Could be either efficacy or safety Could be either efficacy or safety Well defined Well defined Well founded Well founded

Defined measurement or assessment. Defined measurement or assessment. Implies a time point of clinical interest. Implies a time point of clinical interest. If possible, end-points need to be objective measurements rather than subjective outcomes If possible, end-points need to be objective measurements rather than subjective outcomes The primary end-point.

Primary end point measurement will be used to calculate sample size. Statisticians should be consulted. Statisticians should be consulted. Many different ways of calculation depending on whether: Many different ways of calculation depending on whether: –Trial is designed to show superiority against placebo or another treatment. –Trial is designed to show equivalence or non- inferiority against standard treatment Allowance for subjects drop out. Allowance for subjects drop out.

Choice of study design Two main types: Two main types: –Non-Comparative: usually used to assess a treatment’s safety and tolerability. –Comparative design used when comparing treatments: Cross-overParallel-group

Choice of comparative study design Cross-over Parallel group VariabilityMinimal Variability must be taken into account Number of subjects needed SmallerLarger Wash out period between treatments Must be adequate to ensure baseline status No need Disease characteristic Ethically, must be stable during wash out period. No restrictions Primary end-point Subjective No restriction

Bias Selection/ Allocation bias Selection/ Allocation bias Observer bias Observer bias Randomisation Blinding How to avoid it

Subject Selection criteria Define the population to be studied. Define the population to be studied. Inclusion criteria/Exclusion criteria should reflect the wider population of patients. Inclusion criteria/Exclusion criteria should reflect the wider population of patients. Balance the scientific integrity and final application of the treatment in question. Balance the scientific integrity and final application of the treatment in question.

Methodology/ assessments Details of this section ensure that: all observations are performed in a standard manner. all observations are performed in a standard manner. Sample collection procedure and laboratory tests are performed in a standard manner Sample collection procedure and laboratory tests are performed in a standard manner

Ethical considerations: General issues Has every possible precaution been taken to ensure the safety of the subject? Has every possible precaution been taken to ensure the safety of the subject? Are the assessments really necessary, especially those that involve some risk to the subject (e.g. invasive measurements)? Are the assessments really necessary, especially those that involve some risk to the subject (e.g. invasive measurements)? Is the comparator (especially if it is placebo) ethical to use or is the subject being deprived of current proven effective treatment? Is the comparator (especially if it is placebo) ethical to use or is the subject being deprived of current proven effective treatment?

Ethical Considerations: The Declaration of Helsinki It is a statement of clinical principles to provide guidance to physicians and other participants in medical research involving human subjects. It is a statement of clinical principles to provide guidance to physicians and other participants in medical research involving human subjects. It confirm the role of the physician above that of the investigator It confirm the role of the physician above that of the investigator It is a set of principles defining the standards that should apply to biomedical research worldwide. It is a set of principles defining the standards that should apply to biomedical research worldwide.

Ethical Considerations: Informed consent. Often come in two parts: Often come in two parts: –Written information describing the clinical trial –A form which the subject signs to document that he/she has given consent to take part in the study Closely reviewed by ethics committees. Closely reviewed by ethics committees. Consent is valid when freely given. Consent is valid when freely given.

Should include up to date information Should include up to date information That the trial involves research. That the trial involves research. The purpose of the trial (experimental aspects). The purpose of the trial (experimental aspects). Trial treatments and probability for random assignment to each treatment. Trial treatments and probability for random assignment to each treatment. Trial procedures to be followed and Subject’s responsibilities. Trial procedures to be followed and Subject’s responsibilities. Risks, inconveniences, and benefits to the subject. Risks, inconveniences, and benefits to the subject. Ethical Considerations: Informed consent content.

Compensation and/or treatment available to subject in the event of trial-related injury. Compensation and/or treatment available to subject in the event of trial-related injury. That subject’s participation is voluntary and that he/she may refuse to participate or withdraw from the trial at any time. That subject’s participation is voluntary and that he/she may refuse to participate or withdraw from the trial at any time. Monitor(s), Auditor(s), Ethics committee, and regulatory authority(ies) will be granted access to subjects medical records. Monitor(s), Auditor(s), Ethics committee, and regulatory authority(ies) will be granted access to subjects medical records. Confidentiality of subject’s records. Confidentiality of subject’s records. Expected duration of the trial. Expected duration of the trial. Approximate number of trial subjects Approximate number of trial subjects Ethical Considerations: Informed consent content.

Alternative treatments available. Alternative treatments available. Subject’s should not be unduly influenced to participate Subject’s should not be unduly influenced to participate Subjects should be fully informed of all pertinent aspects of the study. Subjects should be fully informed of all pertinent aspects of the study. Written information should be as non-technical as possible. Written information should be as non-technical as possible. Ethical Considerations: Informed consent process.

Subjects must be given ample time to ask questions. Subjects must be given ample time to ask questions. Should be signed and personally dated by the subject (or his/her legally acceptable representative) and by the person who conducted the informed consent discussion. Should be signed and personally dated by the subject (or his/her legally acceptable representative) and by the person who conducted the informed consent discussion.

Case Record Forms Document used to record data on which: Reporting of the clinical trial Reporting of the clinical trial Analysis Analysis Will be based

Purpose of the information collected in the CRF: –To answer the hypothesis formulated in the study protocol –To provide relevant safety data relating to the study drug. Case Record Forms

The CRF should: The CRF should: –Request the precise information required by the protocol. –Request Only the information required by the protocol –Request the information in a way that completion is simple, relatively quick, and as unambiguous as possible, and that all assessment are straight forward to complete –Presents information clearly to enable the investigator to review the subjects continuing eligibility Case Record Forms Design

Summary Study Protocol Study Protocol Scientific consideration Scientific consideration Practical Considerations Practical Considerations Ethical Issues Ethical Issues Collection of Data (Case Record Forms) Collection of Data (Case Record Forms)

GCP COMPLIANCE : Emerging Issues in Worldwide Clinical Trials David A. Lepay, M.D., Ph.D. Director, Division of Scientific Investigations, CDER June 29, 1999

Current Compliance Concerns Most commonly observed deficiencies Most commonly observed deficiencies –Failure to follow the protocol Violation of inclusion/exclusion criteria Violation of inclusion/exclusion criteria Failure to perform required tests Failure to perform required tests –Failure to maintain adequate and accurate records absence of supporting source documents absence of supporting source documents inaccurate or incomplete source documents inaccurate or incomplete source documents

Clinical Investigator Deficiency Categories Protocol Consent Form Records Drug Accountability Adverse Events

–Personally conduct or supervise the investigation* –Ensure that all associates, colleagues, and employees assisting in study conduct are informed about their obligations* –Conduct the study in accordance with the protocol –Comply with all requirements regarding obligations of clinical investigators* –Inform subjects drugs are being used for investigational purposes and ensure informed consent and IRB requirements are met –Report Adverse Events to the sponsor *Delegation high risk YOU ARE AN INVESTIGATOR FULLY COMMITTED TO: